背景:预防SARS-CoV-2症状性感染和先前感染的严重COVID-19,mRNA双剂量疫苗接种,mRNA三剂量疫苗接种,和先前感染和疫苗接种的混合免疫在卡塔尔进行了调查,Beta,和Delta变体。
方法:六个国家,匹配,检测阴性,病例对照研究于2021年1月18日至12月18日期间对239,120项PCR阳性检测和6,103,365项PCR阴性检测进行.
结果:先前感染对Alpha的有效性,Beta,三角洲再感染率为89.5%(95%CI:85.5-92.3%),87.9%(95%CI:85.4-89.9%),和90.0%(95%CI:86.7-92.5%),分别。两剂BNT162b2疫苗接种对α,Beta,Delta感染率为90.5%(95%CI,83.9-94.4%),80.5%(95%CI:79.0-82.0%),和58.1%(95%CI:54.6-61.3%),分别。三剂量BNT162b2疫苗针对Delta感染的有效性为91.7%(95%CI:87.1-94.7%)。先前感染和两剂BNT162b2疫苗接种的混合免疫对Beta感染的有效性为97.4%(95%CI:95.4-98.5%),对Delta感染的有效性为94.5%(95%CI:92.8-95.8%)。先前感染和三剂量BNT162b2疫苗接种对Delta感染的有效性为98.1%(95%CI:85.7-99.7%)。所有五种形式的免疫对严重的,关键,或致命的COVID-19,无论变异。对于mRNA-1273观察到类似的有效性估计。数学模型通过假设先前感染和疫苗接种的个体效应独立起作用来准确地预测混合免疫保护。
结论:混合免疫,提供最强的保护,通过假设从先前的感染和疫苗接种中获得的免疫力独立地起作用来进行数学预测,没有协同作用或冗余。
背景:生物医学研究计划和生物统计学,流行病学,和生物数学研究核心,都在威尔康奈尔医学院-卡塔尔,公共卫生部,哈马德医疗公司,西德拉医学,卡塔尔基因组计划,卡塔尔大学生物医学研究中心,和卡塔尔大学内部补助金IDQUCG-CAS-23/24-114。
BACKGROUND: Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination were investigated in Qatar for the Alpha, Beta, and Delta variants.
METHODS: Six national, matched, test-negative, case-control studies were conducted between January 18 and December 18, 2021 on a sample of 239,120 PCR-positive tests and 6,103,365 PCR-negative tests.
RESULTS: Effectiveness of previous infection against Alpha, Beta, and Delta reinfection was 89.5% (95% CI: 85.5-92.3%), 87.9% (95% CI: 85.4-89.9%), and 90.0% (95% CI: 86.7-92.5%), respectively. Effectiveness of two-dose BNT162b2 vaccination against Alpha, Beta, and Delta infection was 90.5% (95% CI, 83.9-94.4%), 80.5% (95% CI: 79.0-82.0%), and 58.1% (95% CI: 54.6-61.3%), respectively. Effectiveness of three-dose BNT162b2 vaccination against Delta infection was 91.7% (95% CI: 87.1-94.7%). Effectiveness of hybrid immunity of previous infection and two-dose BNT162b2 vaccination was 97.4% (95% CI: 95.4-98.5%) against Beta infection and 94.5% (95% CI: 92.8-95.8%) against Delta infection. Effectiveness of previous infection and three-dose BNT162b2 vaccination was 98.1% (95% CI: 85.7-99.7%) against Delta infection. All five forms of immunity had >90% protection against severe, critical, or fatal COVID-19 regardless of variant. Similar effectiveness estimates were observed for mRNA-1273. A mathematical model accurately predicted hybrid immunity protection by assuming that the individual effects of previous infection and vaccination acted independently.
CONCLUSIONS: Hybrid immunity, offering the strongest protection, was mathematically predicted by assuming that the immunities obtained from previous infection and vaccination act independently, without synergy or redundancy.
BACKGROUND: The Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, Qatar University Biomedical Research Center, and Qatar University Internal Grant ID QUCG-CAS-23/24-114.